标准剂量BEACOPP方案治疗晚期霍奇金淋巴瘤的疗效观察被引量：2

Observation on efficacy of baseline BEACOPP regimen in the treatment of advanced Hodgkin＇ s lymphoma

导出

摘要目的观察标准剂量BEACOPP方案治疗Ⅲ-Ⅳ期霍奇金淋巴瘤（HL）的疗效和安全性。方法20例初治的晚期霍奇金淋巴瘤患者，均接受标准剂量BEACOPP方案化疗，初治肿瘤最大径≥5cm或在化疗后有肿瘤病灶残留的患者给予局部放疗。结果20例患者中14例完全缓解，4例部分缓解，总有效率为90％。主要不良反应为骨髓抑制和肝功能损害，其中2例患者出现Ⅱ度药物性肺损伤，治疗期间未发现治疗相关性死亡。结论标准剂量BEACOPP方案治疗晚期霍奇金淋巴瘤安全有效。 Objective To observe the efficacy of the baseline BEACOPP regimen in the treatment of advanced Hodgkin＇ s lymphoma （HL）. Methods Form January 2009 to January 2011, 20 previously untreated patients with stages Ⅲ-ⅣHL were treated with the modified baseline BEACOPP regimen. Each patient was scheduled to receive 6 - 8 cycles of BEACOPP with consolidation radiotherapy to bulky（≥ 5cm） or residual disease. Results 14 patients achieved a complete remission （CR） and g patients had partial remission （PR）, the total effective rate was 90%. The main toxic effects were bone marrow depression and liver injury. 2 patients had grade 2 drug- induced lung injury. No treatment-related death was observed. Conclusion The baseline BEACOPP regimen is effective and safe for advanced HL.

作者刘晓燕宋亚兰李春霞陈文晟马磊

机构地区广州医学院附属肿瘤医院内三科

出处《国际医药卫生导报》 2013年第16期2500-2502,共3页 International Medicine and Health Guidance News

关键词霍奇金淋巴瘤标准剂量BEACOPP方案 Hodgkin＇ s Lymphoma Baseline BEACOPP regimen

分类号 R733.1 [医药卫生—肿瘤]

引文网络
相关文献

参考文献7

1Aleknavicius E, Valuckas KP, Aleknaviciene B, et al.Treatment results of Hodgkin's lymphoma[J].Medicina (Kaunas), 2009, 45(8): 615-623.
2Evens AM, Hutchings M, Diehl V.Treatment of Hodgkin lymphoma: the past, present, and future[J].Nat Clin Pract Oncol, 2008, 5(9): 543-556.
3Diehl V, Franklin J, Pfreundschuh M, et al.Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease[J].N Engl J Med, 2003, 348(24): 2386-2395.
4Casasnovas O, Coiffier B.Escalated BEACOPP in advanced Hodgkin's lymphoma[J].Lancet, 2012, 379(9528): 1767- 1768.
5Bredenfeld H, Franklin J, Nogova L, et al.Severe pulmonary toxicity in patients with advanced-stage Hodgkin's disease treated with a modified bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone, and gemcitabine (BEACOPP) regimen is probably related to the combination of gemcitabine and bleomycin: a report of the German Hodgkin's Lymphoma Study Group[J].J Clin Oncol, 2004, 22(12): 2424-2429.
6周际昌.实用肿瘤内科学[M].2版.北京人民卫生出版社,2005:291-293.
7Ballova V, R fi ffer JU, Haverkamp H, et al.A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly)[J].Ann Oncol, 2005, 16(1)- 124-131.